NCT00197288已完成3 期
A Phase III, Observer-blind, Randomized Study to Evaluate the Immunogenicity and Safety of Fluarix™ (GlaxoSmithKline Biologicals) Compared With Fluzone® (Aventis Pasteur) Administered Intramuscularly in Adults 18 Years and Older in the U.S.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,847
- 试验地点
- 16
- 主要终点
- Immunological non-inferiority (GMT & seroconversion rates) of Fluarix vs Fluzone 21 days post-vaccination in adults (18 yrs)
研究概览
简要总结
The purpose of this study is to compare two licensed influenza vaccines (Fluzone and Fluarix) in terms of the immune response elicited and the safety/ any symptoms that may occur for up to six months after vaccination.
详细描述
- Experimental design: multi-center, randomized (1:1), observer-blind, active-controlled study in 2 parallel groups with approximately:
- Study vaccine: full dose of Fluarix by IM administration.
- Control vaccine: full dose of Fluzone by IM administration.
- Two scheduled visits per subject at days 0 (visit 1) and 21(visit 2) with blood sample collected at each visit to evaluate the immune response. There will be a final contact with each subject 6 months after vaccination for safety follow up and study conclusion.
- Vaccination schedule: one IM injection at day 0.
- Type of study: Self contained.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All adults 18 years and older.
- •Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., return for follow-up visit and completion of the diary cards) should be enrolled in the study.
- •Written informed consent obtained from the subject.
- •If the subject is female, she must be of non-childbearing potential, i.e. either surgically sterilized or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions .
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period.
- •Has received any other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study.
- •History of hypersensitivity to a previous dose of influenza vaccine.
- •History of allergy or reactions likely to be exacerbated by any component of the vaccine(s) including egg, chicken protein, gelatine, formaldehyde, gentamicin sulphate, thimerosal or sodium deoxycholate.
- •Acute disease at the time of enrollment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e. Oral temperature <37.5°C (99.5°F) / Axillary temperature <37.5°C (99.5°F)).
- •History of Guillain Barré syndrome within 6 weeks of prior receipt of inactivated influenza virus vaccine.
- •Pregnancy and lactating females.
结局指标
主要结局
Immunological non-inferiority (GMT & seroconversion rates) of Fluarix vs Fluzone 21 days post-vaccination in adults (18 yrs)
次要结局
- Immuno comparison of Fluarix vs Fluzone post-vacc in immunologically -competent, -compromised, overall, stratified by age
- Safety comparison (sol local, general & unsol AEs, SAEs)
- Non-inferiority of Fluarix vs Fluzone 21 days post-vacc in elderly (>65 yrs)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
3 期
Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in ChildrenInfluenzaNCT00383123GlaxoSmithKline3,327
已完成
2 期
Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in ChildrenInfluenzaNCT00408395Novartis Vaccines281
已完成
2 期
Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding WomenInfluenzaNCT01181323National Institute of Allergy and Infectious Diseases (NIAID)240
已完成
1 期
Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and AdolescentsInfluenzaHIV InfectionsNCT00091702National Institute of Allergy and Infectious Diseases (NIAID)300
已完成
3 期
Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, QuadrivalentSeasonal InfluenzaNCT05431725Sinovac Biotech Co., Ltd2,202